Lymphoma updates: CAR-T, brentuximab & nivolumab

Brentuximab vedotin + nivolumab in lymphomaПодробнее

Brentuximab vedotin combined with nivolumab for Hodgkin lymphomaПодробнее

Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphomaПодробнее

Updates on frontline brentuximab vedotin for peripheral T-cell lymphomaПодробнее

Dr. Hamdan on the Potential Use of Brentuximab Vedotin/Nivolumab in Hodgkin LymphomaПодробнее

Lymphoma updates: CAR-T, brentuximab & nivolumabПодробнее

RadVax trial: nivolumab and low-dose radiation in patients with R/R Hodgkin lymphomaПодробнее

Latest updates in lymphoma trialsПодробнее

Franco Cavalli, Talk - Cancer Immunology makes it to clinicПодробнее

Updates on the use of nivolumab in Hodgkin lymphoma & how this agent may impact treatmentПодробнее

SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HLПодробнее

E4412 update: ipi-nivo-brentuximab for R/R Hodgkin lymphomaПодробнее

Nivolumab and pembrolizumab and the current treatment landscape for Hodgkin lymphomaПодробнее

Updates on the brentuximab vedotin for CTCLПодробнее

ALCANZA: brentuximab vedotin improves ORR and PFS in CTCLПодробнее

Maintenance nivolumab in post-stem cell transplant Hodgkin lymphomaПодробнее

Update on CAR T Cell Therapy for Diffuse Large B-Cell Lymphoma | LRF WebinarsПодробнее

R/R lymphoma: checkpoint blockade and transplantationПодробнее

Ipilimumab, nivolumab & brentuximab vedotin for R/R Hodgkin lymphomaПодробнее

A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin LymphomaПодробнее

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin LymphomaПодробнее